These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 12741364)

  • 1. AIDS drug in halted trial less effective as monotherapy.
    AIDS Read; 2003 Apr; 13(4):159. PubMed ID: 12741364
    [No Abstract]   [Full Text] [Related]  

  • 2. Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Trizivir vs. efavirenz: results from ACTG 5095.
    Feinberg J
    AIDS Clin Care; 2003 Sep; 15(9):78-9. PubMed ID: 14669723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AIDS foundation seeks withdrawal of approval for HIV drug combination.
    Clarke B
    Lancet Infect Dis; 2003 Oct; 3(10):604. PubMed ID: 14558502
    [No Abstract]   [Full Text] [Related]  

  • 4. Top stories of 2004. ACTG 5095: efavirenz beats AZT + 3TC + abacavir.
    del Rio C
    AIDS Clin Care; 2005 Jan; 17(1):4. PubMed ID: 15717367
    [No Abstract]   [Full Text] [Related]  

  • 5. [Ensuring high adherence. Clever combination assures therapeutic success].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():38-9. PubMed ID: 15011583
    [No Abstract]   [Full Text] [Related]  

  • 6. Anatomy of a study: Trizivir vs. Sustiva.
    Berger DS
    Posit Aware; 2003; 14(3):40-1. PubMed ID: 12866492
    [No Abstract]   [Full Text] [Related]  

  • 7. Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
    Feinberg J
    AIDS Clin Care; 2006 Nov; 18(11):99. PubMed ID: 17183745
    [No Abstract]   [Full Text] [Related]  

  • 8. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection.
    Ruane P; Lang J; DeJesus E; Berger DS; Dretler R; Rodriguez A; Ward DJ; Lim ML; Liao Q; Reddy S; Clair MS; Vila T; Shaefer MS
    HIV Clin Trials; 2006; 7(5):229-36. PubMed ID: 17162316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
    Shey MS; Kongnyuy EJ; Alobwede SM; Wiysonge CS
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD005481. PubMed ID: 23543540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abacavir arm stopped in clinical trial.
    James JS
    AIDS Treat News; 2003 Apr; (390):6-7. PubMed ID: 12739475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of co-formulated zidovudine, lamivudine and abacavir (Trizivir) on antiretroviral-naive patients presenting with advanced HIV-1 infection.
    Seaton RA; Fox R; Bodasing N; Peters SE; Gourlay Y
    AIDS; 2003 Feb; 17(3):445-7. PubMed ID: 12556701
    [No Abstract]   [Full Text] [Related]  

  • 12. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
    HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conference report - antiretroviral therapy update from the 9th European AIDS Conference.
    Conway B
    MedGenMed; 2003 Dec; 5(4):30. PubMed ID: 14745377
    [No Abstract]   [Full Text] [Related]  

  • 14. Where now for Trizivir? Role of the triple-NRTI pill post-ACTG 5095.
    Moyle GJ
    AIDS Read; 2003 May; 13(5):223-4, 227, 244. PubMed ID: 12800825
    [No Abstract]   [Full Text] [Related]  

  • 15. [First HIV triple therapy with one tablet].
    Dtsch Med Wochenschr; 2000 Feb; 125(8):A22. PubMed ID: 10723466
    [No Abstract]   [Full Text] [Related]  

  • 16. Antiretroviral rounds. When success is a pain.
    Bartlett JG; del Rio C
    AIDS Clin Care; 2001 Aug; 13(8):74-5. PubMed ID: 11547461
    [No Abstract]   [Full Text] [Related]  

  • 17. We want our Trizivir!
    Vázquez E
    Posit Aware; 2003; 14(5):25-6. PubMed ID: 14679938
    [No Abstract]   [Full Text] [Related]  

  • 18. High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.
    Gupta RK; Goodall RL; Ranopa M; Kityo C; Munderi P; Lyagoba F; Mugarura L; Gilks CF; Kaleebu P; Pillay D;
    Clin Infect Dis; 2014 Apr; 58(7):1023-6. PubMed ID: 24352348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.
    Moyle GJ; Gazzard BG
    AIDS; 2002 May; 16(7):1086-7. PubMed ID: 11953482
    [No Abstract]   [Full Text] [Related]  

  • 20. An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
    Moyle G; Higgs C; Teague A; Mandalia S; Nelson M; Johnson M; Fisher M; Gazzard B
    Antivir Ther; 2006; 11(1):73-8. PubMed ID: 16518962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.